Angiostasis and vascular regression in chronic granulomatous inflammation induced by diclofenac in combination with hyaluronan in mice.
Angiostasis and vascular regression in chronic granulomatous inflammation was assessed in mice induced with diclofenac in combination with hyaluronan. The local injection of 0.1 mL HYAL EX-0001 (0.18% diclofenac in 2.5% hyaluronan) reduced granulomatous development after six days treatment from 150.4 +/- 13.8 (0.18 saline) to 117.1 +/- 17.8 mg (dry weight, n = 10), but not significantly when compared with 0.1 mL 2.5% hyaluronan alone or diclofenac in 0.1 mL saline. Diclofenac administered in saline had no significant effect when compared with saline control. The vascular density, expressed as carmine content per mg dry weight tissue, in those animals treated with HYAL EX-0001 was also significantly reduced to 5.27 +/- 0.55 micrograms mg-1 (P < 0.1, n = 10) when compared with saline control (7.99 +/- 1.0), hyaluronan alone (7.20 +/- 1.0), and diclofenac in saline. (7.36 +/- 1.28). A similar profile of activity was seen on topical application except that all treatments did not affect granulomatous tissue development. On therapeutic dosing of mice daily with HYAL EX-0001 from day 7 after induction of the granulomatous tissue, the granulomatous tissue development was dramatically reduced from 111.67 +/- 4.40 mg (n = 14 on day 7) to 60.23 +/- 7.22 (P < 0.001, n = 8 on day 14) and 54.98 +/- 7.88 (P < 0.001, n = 8 on day 21). HYAL EX-0001 after 14 days of application significantly reduced granulomatous tissue mass when compared with the hyaluronan-dosed control on day 21 (89.58 +/- 7.49, P = 0.01, n = 8).(ABSTRACT TRUNCATED AT 250 WORDS)
D000287:Administration, Topical; D000818:Animals; D001808:Blood Vessels / Q000473:pathology*; D002908:Chronic Disease; D004008:Diclofenac / Q000008:administration & dosage / Q000494:pharmacology*; D004338:Drug Combinations; D005260:Female; D006099:Granuloma / Q000188:drug therapy* / Q000473:pathology; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D008815:Mice, Inbred Strains; D009389:Neovascularization, Pathologic / Q000473:pathology
D004338:Drug Combinations; D004008:Diclofenac; D006820:Hyaluronic Acid